# Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

> **NCT04442347** · PHASE1 · COMPLETED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Ornithine Transcarbamylase Deficiency

## Interventions

- **BIOLOGICAL:** ARCT-810
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04442347
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-03
- **Primary completion:** 2023-08-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442347, "Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04442347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*